Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.75 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.75 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CKS1B | P61024 | 1/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162519 | 0.96 | CYP4A11 (0.72) | CYP4A11CYP4F2LOXL2CCR6HKDC1 | |
| SCHEMBL317577 | 0.89 | CYP4A11 (0.66) | CYP4A11CYP4F2LOXL2CCR6HKDC1 | |
| SCHEMBL9763407 | 0.88 | CYP4A11 (0.60) | CYP4A11CYP4F2LOXL2CCR6HKDC1 | |
| SCHEMBL10610477 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2CCR6HKDC1 | |
| SCHEMBL1628660 | 0.86 | CYP4A11 (1.00) | CYP4A11CYP4F2LOXL2CCR6HKDC1 | |
| SCHEMBL10641751 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL8044139 | 0.86 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2THRATHRB | |
| SCHEMBL18158247 | 0.85 | CYP4A11 (0.65) | CYP4A11CYP4F2LOXL2CCR6HKDC1 | |
| SCHEMBL19889904 | 0.85 | CYP4A11 (0.69) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL70185 | 0.85 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2CCR6HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397614-B1 | IONIZABLE CATIONIC LIPID | ARCTURUS THERAPEUTICS INC (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2017117530-A9 | IONIZABLE CATIONIC LIPID | ARCTURUS THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20180050987-A1 | AROMATIC IONIZABLE CATIONIC LIPID | ARCTURUS THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-9834510-B2 | Aromatic ionizable cationic lipid | ARCTURUS THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834510-B2 | Aromatic ionizable cationic lipid | ARCTURUS THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| WO-2017117530-A1 | IONIZABLE CATIONIC LIPID | ARCTURUS THERAPEUTICS, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170190661-A1 | Aromatic Ionizable Cationic Lipid | ARCTURUS THERAPEUTICS, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170190661-A1 | Aromatic Ionizable Cationic Lipid | ARCTURUS THERAPEUTICS, INC. | 2017-07-06 | — | — | US | disclosed |
| EP-2346830-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck Sharp & Dohme Corp. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010098994-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010093535-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010030722-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-0664281-B1 | ISOCARBACYCLIN WITH MODIFIED alpha(a)-CHAIN AND PROCESS FOR PRODUCING THE SAME | TEIJIN LTD (JP) | 1997-05-28 | — | — | EP | disclosed |
| EP-0664281-A1 | ISOCARBACYCLIN WITH MODIFIED $g(a)-CHAIN AND PROCESS FOR PRODUCING THE SAME | TEIJIN LIMITED (JP) | 1995-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050987-A1 | AROMATIC IONIZABLE CATIONIC LIPID | SGMS1, SLCO4C1, SLCO2B1 | CYP4A11 433/4885CYP4F2 643/4885LOXL2 427/4885 |
| US-20170190661-A1 | Aromatic Ionizable Cationic Lipid | SGMS1, SLC7A1, SLCO2B1 | CYP4A11 476/4885CYP4F2 494/4885LOXL2 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.